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LETTERS TO THE EDITORRegarding “The inﬂuence of gender on patency rates
after iliac artery stenting”
We read with great interest the results by Bechter-Hugl et al1
regarding the impact of gender on primary outcomes after iliac ar-
tery stenting. The authors conclude that although women are
older and present with a more advanced stage of peripheral arterial
occlusive disease, endovascular therapy is equally effective irrespec-
tive of gender. Moreover, restenosis, primary patency, and second-
ary patency rates were similar between men and women.
However, most of the studies addressing this matter lead to
opposing results, highlighting the impact of gender and question-
ing the main conclusions of Bechter-Hugl et al.1 According to a
large-scale retrospective analysis of more than 20,000 cases by
Goode et al,2 outcomes after iliac artery stenting were signiﬁcantly
worse with increasing age and female sex. Moreover, the authors
showed that the risk of death after elective iliac angioplasty or
stenting was signiﬁcantly higher in women (multivariable odds ra-
tio, 4.98, 2.09-13.26). Furthermore, data from the Dutch Iliac
Stent Trial3 indicate that gender remains a major predictor of
whether a patient would require iliac reintervention. In addition,
Timaran et al4 underline that women undergoing external iliac ar-
tery angioplasty with stent placement have signiﬁcantly reduced
primary patency rates. Despite initial technical success, the authors
conclude that these patients are at increased risk of long-term fail-
ure and might require subsequent procedures to obtain clinical
success. Finally, in another study by the same authors, women un-
dergoing iliac angioplasty and stenting for limb-threatening
ischemia were shown to have signiﬁcantly reduced primary stent
patency rates and may need additional procedures to obtain satis-
factory clinical improvement and limb salvage.5
Apparently, there is no consensus supporting the conviction that
sex does not inﬂuence the outcomeof iliac artery revascularization.Or
does it? After evaluating the conclusions of Bechter-Hugl et al,1 it is
clear that there is a high diversity of results between studies so far con-
cerning the impact of gender on treatment of iliac artery occlusive dis-
ease. Hence, most of these studies are retrospective or observational
studies, and therefore it is justiﬁed to generate prospectively planned
and randomly enrolling trials to better address this matter. Although
thehighnumberofpatients included in retrospective studies is amajor
advantage that leads to more powerful statistical results, the superior-
ity of randomized trials and the weakness of retrospective studies to
address clinical investigation have been shown with evidence.
In a recent comment of ours regarding the impact of gender on
stenting for the treatment of femoropopliteal disease, we underlined
that the real impact of gender on early and late outcomes after pe-
ripheral arteries revascularization could be addressed only through
prospectivelyplanned, randomized trials avoiding all possible patient
selection bias and unequal distribution of risk factors at baseline.6
The same basic principle applies for iliac occlusive disease as well.
In conclusion, the real differences between men and women
regarding patency rates after iliac artery stenting could be reﬂected
only through prospective trials with strictly designed methodology.
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Reply
Our study was speciﬁcally designed to assess the impact of
gender on outcome after iliac artery stenting.1 To our knowledge,
only one study with a comparable approach has been published
previously.2 However, case numbers were considerably smaller
and the rate of TransAtlantic Inter-Society Consensus type C
and D lesions was clearly higher in the collective investigated by
Timaran et al,2 which might well explain the differing results.
The cited Dutch Iliac Stent Trial, similar to most other studies
published to date, does treat gender as a common risk factor.3
Moreover, the multivariate risk factor analysis referred to the total
collective without differentiation between reinterventions after
percutaneous transluminal angioplasty (PTA) and stent-PTA,
whereas we investigated the outcome after primary stent-PTA
solely.
The large retrospective analysis of 23,308 cases by Goode
et al4 included cases with and without stent placement. Further-
more, the inferior outcome in women refers to the overall proce-
dural complication rate rather than to long-term outcome, and
no particulars on the nature of complications have been given.
However, these data do not contradict our results, as we have
also experienced a higher incidence of procedure-related complica-
tions in women.
We do agree with Dr Galyfos that the impact of gender on
the outcome of patients with iliac occlusive disease requiring
revascularization therapy is unclear. The differences in the popu-
lation of patients analyzed, the different end points used in these
studies, and the different approaches and techniques used might
all confound the conﬂicting results. Whereas our report includes
the most female patients with long-term follow-up, the retrospec-
tive nature of our analysis precluded an unequivocal clariﬁcation
of the impact of gender on patency after iliac artery stenting.
On the contrary, our data raised an additional questiondwhether
young female patients are at speciﬁcally high risk for a less favor-
able outcome. It is obvious that these questions should be
addressed in a prospective manner with a well-deﬁned population
of patients. A prospective study would have to include male and
female populations of identical size, matched for age, extent of269
